At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 122 enrolled
Drug / intervention
Metal Allergen Epicutaneous Patchbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study
In Brief
A Phase 2 clinical trial evaluating Metal Allergen Epicutaneous Patch for Dermatitis, Eczematous. Completed, enrolled 122 participants across 8 sites in 6 countries.
Detailed Summary
48-hour application of metal allergen patches to test for potential allergic responses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Eczematous
CountriesGermany, Italy, Japan, Netherlands, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedNov 2015
Enrollment StartDec 2016
Primary CompletionJul 2019
TodayJul 2026
First PostedNov 26, 2015
Enrollment StartDec 5, 2016
Primary CompletionJul 15, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.6 years ago
Interventions
Metal Allergen Epicutaneous Patchbiological
48 hour application of metal allergen patch to diagnose contact dermatitis